Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
The paper is devoted to improvement of bladder cancer diagnostics quality in an outpatient setting by means of using the high-tech equipment – multiparametric magnetic resonant tomography as well as studying correlation between the depth of invasion and tumor size in patients first applied to the outpatient facilities and after surgical treatment.
bladder cancer, cystoscopy, bladder biopsy, multiparametric magnetic resonant tomography, outpatient facilities
1. Rak mochevogo puzyrya // Federal'nye klinicheskie rekomendacii. – Moskva. – 2021.
2. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics // CA A Cancer J. Clin. – 2022, 72, 7–33. https://doi.org/10.3322/caac.21708
3. Gluhov A.I., Potoldykova N.V., Gordeev S.A., Vinarov A.Z., Polyakovskiy K.A., Rapoport L.M., Carichenko D.G., Enikeev D.V., Glybochko P.V. Sovremennye tendencii v diagnostike raka mochevogo puzyrya // Urologiya. – 2018. – № 3. – S. 100–105. doi: https://dx.doi.org/10.18565/urology.2018.5.100–105
4. Kaprin A.D., Starinskiy V.V., Shahzodova A.O. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost') // Moskva. – MNIOI im. P.A. Gercena. − 2022.
5. Kaprin A.D., Starinskiy V.V., Shahzodova A.O. Zlokachestvennye novoobrazovaniya v Rossii v 2019 godu (zabolevaemost' i smertnost'). Moskva. – MNIOI im. P.A. Gercena. − 2020.
6. Roger Chou, Tracy Dana screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force // Ann Intern Med. – 2010. – Oct 5; 153(7): 461-8. doi:https://doi.org/10.7326/0003-4819-153-7- 201010050-00009
7. Adeishvili G.Z. Ocenka diagnosticheskoy i prognosticheskoy znachimosti citokeratinov u bol'nyh rakom mochevogo puzyrya / Avtoref. dis. kand. med. nauk: 14.01.12 // SPb. – 2017. – C. 20.
8. Al'-Shukri S.H., Korneev I.A. Obschie principy lecheniya bol'nyh rakom mochevogo puzyrya // Moskovskoe onkologicheskoe obschestvo. – 2003.
9. Shiryaev A.A., Govorov A.V., Vasil'ev A.O., Okishev A.V., Kim Yu.A., Fedina M.S., Bykov P.I., Pushkar' D.Yu. Molekulyarnye biomarkery v diagnostike raka mochevogo puzyrya // Onkourologiya. – 2020. – T. 16. – № 1. – S. 100–105.
10. van Rhijn B.W., van der Poel H.G., van der Kwast T.H. Urine Markers for Bladder Cancer Surveillance: A Systematic Review // Eur. Urol. – 2005. – 47, 736–748. https://doi.org/10.1016/j.eururo.2005.03.014.
11. Karakiewicz P.I., Benayoun S., Zippe C., Ludecke G., Boman H., Sanchez‐Carbayo M., Casella R., Mian C., Friedrich M.G., Eissa S. et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder // BJU Int. – 2006. – 97, 997–1001. https://doi.org/10.1111/ j.1464‐410X.2006.06036.x
12. Lokeshwar V.B., Habuchi T., Grossman H.B., Murphy W.M., Hautmann S.H., Hemstreet G.P., Bono A.V., Getzenberg R.H., Goebell P., Schmitz‐Dräger B.J. et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers // Urology. – 2005. – 66, 35–63. https://doi.org/10.1016/ j urology.2005.08.064
13. Babjuk M., Burger M., Compérat E.M., Gontero P., Mostafid A.H., Palou J., van Rhijn B.W.G., Roupret M., Shariat S.F., Sylvester R. et al. European Association of Urology Guidelines on Non‐muscle‐invasive Bladder Cancer (TaT1 and Carcinoma In Situ) ‐ 2019 Update // Eur. Urol. – 2019. – 76, 639–657. https://doi.org/10.1016/ j.eururo.2019.08.016
14. Fonteyne V., Ost P., Bellmunt J. et al. Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review // Eur. Urol. – 2018. – Vol. 73. – R. 40–50. doi:https://doi.org/10.1016/j.eururo.2017.03.019
15. Wasco M.J., Daignault S., Zhang Y., Kunju L.P., Kinnaman M., Braun T., Lee C.T., Shah R.B. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection // Urology. – 2007. – Jul; 70(1): 69-74. doi:https://doi.org/10.1016/j.urology.2007.03.033. PMID: 17656211
16. Barocas D.A., Boorjian S.A., Alvarez R.D., Downs T.M., Gross C.P., Hamilton B.D., Kobashi K.C., Lipman R.R., Lotan Y., Ng C.K., Nielsen M.E., Peterson A.C., Raman J.D., Smith-Bindman R., Souter L.H. Microhematuria: AUA/SUFU Guideline // J Urol. – 2020. – Oct; 204(4): 778-786. doi: 10.1097/ JU.0000000000001297
17. Deo S.V., Shukla N.K., Sandhu M., Thakur K.K., Goel S., Mohanti B.K., Rath G.K. Role of transabdominal pelvic ultrasound and computed tomography in the detection of bladder involvement in advanced cancer of the cervix // Australas Radiol. – 1996. – Aug; 40(3): 218-20. doi:https://doi.org/10.1111/j.1440-1673.1996.tb00388.x
18. Lee C.H., Tan C.H., Faria S.D.C. et al. Role of imaging in the local staging of urothelial carcinoma of the bladder // Am J Roentgenol. – 2017; 208: 1193–1205.
19. Séguier D., Puech P., Kool R., Dernis L., Gabert H., Kassouf W., Villers A., Marcq G. Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging- Reporting and Data System (VI-RADS) performance and potential clinical applications // Ther Adv Urol. – 2021. – Aug 25; 13:17562872211039583. doi:https://doi.org/10.1177/17562872211039583
20. Pecoraro M., Takeuchi M., Vargas H.A., Muglia V.F., Cipollari S., Catalano C., Panebianco V. Overview of VI-RADS in Bladder Cancer // AJR Am. J. Roentgenol. – 2020; 214:1259–1268. doi:https://doi.org/10.2214/AJR.20.22763
21. Mischenko A.V., Vasil'ev A.V., Petrova A.S., Danilov V.V. Osnovy sistemy VI-RADS – koncepcii mul'tiparametricheskoy magnitno-rezonansnoy tomografii pri rake mochevogo puzyrya // Luchevaya diagnostika i terapiya. – 2019. – № 3. – S. 5–13. doi: http://dx.doi.org/10.22328/2079-5343-2019-10-3-5-13
22. Panebianco V., Narumi Y., Altun E., Bochner B.H., Efstathiou J.A., Hafeez S., Catto J.W.F. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System) // European Urology. – 2018. – 74(3), 294–306. doi:https://doi.org/10.1016/j.eururo.2018.04.029
